Contribution: Industrial Research Assistance Program – Contributions to Firms
Mediphage Bioceuticals, Inc.
$63,380.00
UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies
EF 2026-27 · 2027-01-01
Résumé
As part of the international consortium project “UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies”, this project's objective is to use Chromatin Bio's bioinformatics platform to design novel gene regulatory elements, improving gene expression in Mediphage therapeutic constructs for Stargardt disease, while reducing sequence complexity and increasing manufacturing yields. Once generated, these constructs will be complexed with Entos proprietary ocular nanocarrier for in vivo evaluation by NRC and Entos. The best performing candidates will then be manufactured as msDNA drug substances for further therapeutic development.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Toronto|Toronto, Ontario, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
788308328
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2027-03-26
Agreement Number
1034675
Agreement Start Date
2027-01-01
Agreement Title
UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies
Agreement Title (French)
UK Biomanufacturing - 10143578 - NPmsDNA2024 - Développement de thérapies géniques non virales ciblées in vivo
Agreement Type
Contribution
Agreement Value
$63,380.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
As part of the international consortium project “UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies”, this project's objective is to use Chromatin Bio's bioinformatics platform to design novel gene regulatory elements, improving gene expression in Mediphage therapeutic constructs for Stargardt disease, while reducing sequence complexity and increasing manufacturing yields. Once generated, these constructs will be complexed with Entos proprietary ocular nanocarrier for in vivo evaluation by NRC and Entos. The best performing candidates will then be manufactured as msDNA drug substances for further therapeutic development.
Description (French)
Dans le cadre du projet de consortium international « UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies », l’objectif de ce projet est d’utiliser la plateforme bioinformatique de Chromatin Bio pour concevoir de nouveaux éléments de régulation génique, améliorant l’expression des gènes dans les constructions thérapeutiques Mediphage pour la maladie de Stargardt, tout en réduisant la complexité des séquences et en augmentant les rendements de fabrication. Une fois générées, ces constructions seront complexées avec le nanocarrier oculaire exclusif d’Entos pour une évaluation in vivo par le CNRC et Entos. Les candidats les plus performants seront ensuite fabriqués en tant que substances médicamenteuses msDNA en vue d’un développement thérapeutique ultérieur.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
788308328
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Mediphage Bioceuticals, Inc.
Recipient Operating Name
Mediphage Bioceuticals, Inc.
Recipient Postal Code
M5G 0B7
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2025-2026-Q2-1034675
